Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue International Journal of Cancer Année : 2023

Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort

Alessandra Allione
Clara Viberti
  • Fonction : Auteur
Ilaria Cotellessa
  • Fonction : Auteur
Chiara Catalano
  • Fonction : Auteur
Elisabetta Casalone
  • Fonction : Auteur
Giovanni Cugliari
Alessia Russo
Simonetta Guarrera
Darío Mirabelli
  • Fonction : Auteur
Carlotta Sacerdote
Marco Gentile
  • Fonction : Auteur
Fabian Eichelmann
  • Fonction : Auteur
Matthias Bernd Schulze
Sophia Harlid
Anne Kirstine Eriksen
  • Fonction : Auteur
A. Tjønneland
Martin Andersson
  • Fonction : Auteur
Martijn E.T. Dollé
  • Fonction : Auteur
Heleen van Puyvelde
  • Fonction : Auteur
Elisabete Weiderpass
  • Fonction : Auteur
Miguel Rodriguez-Barranco
A. Agudo
Alicia K. Heath
  • Fonction : Auteur
María Dolores Chirlaque
  • Fonction : Auteur
Sabina Sieri
Torkjel Manning Sandanger
  • Fonction : Auteur
Eva E. Ardanaz
Paolo Vineis
  • Fonction : Auteur
Giuseppe Matullo

Résumé

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer mainly caused by asbestos exposure. Specific and sensitive noninvasive biomarkers may facilitate and enhance screening programs for the early detection of cancer. We investigated DNA methylation (DNAm) profiles in MPM prediagnostic blood samples in a case-control study nested in the European Prospective Investigation into Cancer and nutrition (EPIC) cohort, aiming to characterise DNAm biomarkers associated with MPM. From the EPIC cohort, we included samples from 135 participants who developed MPM during 20 years of follow-up and from 135 matched, cancer-free, controls. For the discovery phase we selected EPIC participants who developed MPM within 5 years from enrolment (n = 36) with matched controls. We identified nine differentially methylated CpGs, selected by 10-fold cross-validation and correlation analyses: cg25755428 (MRI1), cg20389709 (KLF11), cg23870316, cg13862711 (LHX6), cg06417478 (HOOK2), cg00667948, cg01879420 (AMD1), cg25317025 (RPL17) and cg06205333 (RAP1A). Receiver operating characteristic (ROC) analysis showed that the model including baseline characteristics (age, sex and PC1wbc) along with the nine MPM-related CpGs has a better predictive value for MPM occurrence than the baseline model alone, maintaining some performance also at more than 5 years before diagnosis (area under the curve [AUC] < 5 years = 0.89; AUC 5-10 years = 0.80; AUC >10 years = 0.75; baseline AUC range = 0.63-0.67). DNAm changes as noninvasive biomarkers in prediagnostic blood samples of MPM cases were investigated for the first time. Their application can improve the identification of asbestos-exposed individuals at higher MPM risk to possibly adopt more intensive monitoring for early disease identification.

Domaines

Cancer
Fichier principal
Vignette du fichier
Intl Journal of Cancer - 2022 - Allione - Blood cell DNA methylation biomarkers in preclinical malignant pleural.pdf (1.23 Mo) Télécharger le fichier
Origine Accord explicite pour ce dépôt

Dates et versions

hal-04068536 , version 1 (11-05-2023)

Identifiants

Citer

Alessandra Allione, Clara Viberti, Ilaria Cotellessa, Chiara Catalano, Elisabetta Casalone, et al.. Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort. International Journal of Cancer, 2023, 152 (4), pp.725-737. ⟨10.1002/ijc.34339⟩. ⟨hal-04068536⟩
12 Consultations
16 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More